Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does sound put on. Just a three years ago this stock ran to $30. I think the shorts are boxed in.
I expect it to be EXCELLENT!
Well this is the AVXL board. The Rett videos are powerful and nice to see.
Very sorry for such a loss as you have gone through. I will pray for healing and restoration for you and your wife.
Well then proclaiming failure is silly too. Avatar was reported as primary and secondary efficacy end points being met.
"Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms with related changes in potential biomarkers (GABA and L-AAA) of disease pathology"
I look forward to the EXCELLENCE results.
When comparing Blarcamesine to the only approved drug Daybue there's no question in my mind that Blarcamesine will be approved. The bar has been set low and the recent Rett videos are a powerful testimony. I look forward to 2024.
Actually $800 is good enough for me.
Yes I realize there are implications but it's the way it is. These types are a dime a dozen.
Those darn parents bahahaha. Nothings going to hold this puppy down on lift off.
Here's to a great 2024. Merry Christmas all.
Included in the videos there are EXCELLENT studies not just AVATAR. Very compelling evidence A-273 is working.
Also- Feb 1, 2022
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints
Yep no NDA announcement just yet.
Your likely right in that the CRO wouldn't release the data package until all safety evaluations were completed. I believe "they" the CRO is still holding results but also since the unblinding I imagine Missling has a good grasp of those results by now.
Wow such harsh language he must be really sweating.
So you have in depth knowledge of RNA DNA studies?
I think the shorts are about to derail. Watch the videos.
I watched the videos and to hear first hand evidence that seizures have subsided and no side effects is powerful.
https://www.facebook.com/rettaustralia
I think clearly from the CC the push back was due to the safety follow up and Missling pretty much as admitted Rett read out wouldn't be this year.
Soumit Roy
I see. And one last question on the Rett program. Could you give us a little color, when are you still expecting the data? Is it going to be before the year end 2023? And is there any delay or is it an expected safety window that you have follow-up that you have to -- you are doing which is why pushing the data back.
Christopher Missling
Yes, after the last 12-week readout, there was an additional safety follow-up and that's basically why the timing is maybe a little bit different from expectations, but we are on track to release this data once we have it.
Sounds as if they have the trial data but are now awaiting the final safety out come.
I see 3100 traded with 100000 at the ask.
edit- ihub currently showing 20000 traded
Many thanks for posting the Fox Business video. Good to hear Anavex mentioned.
Agree. Also saying the FDA has made a decision regarding A-273 would be a material event that the company would have had to release to the public.
The person may get caught but it's always after the fact and then it's too late.
I would think it's more to the line of private discussions.
AF gives you water to carry. Carry on.
Great find PJ!!
A fart is all he's got at this point.
Selling for capital tax loss could put one under wash sale rules. You'll need to wait 30 days to buy back same ticker. With news coming seems a risky move. My opinion.
Map covered with red and orange shows worrying spread of deadly fungus across the US
https://www.msn.com/en-us/health/medical/map-covered-with-red-and-orange-shows-worrying-spread-of-deadly-fungus-across-the-us/ar-AA1lDrYg
"Brilacidin’s ability to potentiate marketed antifungals, such as caspofungin, in multiple human pathogenic fungi, while showing strong stand-alone potency against the hard-to-treat fungal pathogen, C. neoformans, clearly supports Brilacidin’s potential to be developed as a novel antifungal".
Somebody wake up Leo
I think it's more to the fact that ihub sells a subscription for real time.
Where is it written that said peer review expected by year end?
Oh I'm quite sure it will gain approval. Thanks for your concerns though.
I will also sell some at new highs.
The low price over these last several months has given me time to accumulate. I consider myself fortunate.
It's all coming together-- "Among participants with early symptomatic AD, blarcamesine was generally safe, well tolerated and
significantly slowed clinical progression at 48 weeks"
Several hit pieces drained investors money in 2015. Terrible what happened. God sees all.
Never wrong and when cornered ridicule.
Looking at clinicaltrials.com- Inputting NCT04314934 for OLE ANAVEX®2-73-AD-EP-004 takes you to OLE Phase 2b/3 Study ANAVEX2-73-AD-004 (ATTENTION-AD).
Are they not the same.
PR October 13, 2021-
About ANAVEX®2-73-AD-004 Clinical Study (ClinicalTrials.gov Identifier: NCT03790709) and OLE ANAVEX®2-73-AD-EP-004 Clinical Study ATTENTION-AD (ClinicalTrials.gov Identifier: NCT04314934)
Seems shorts are grasping at straws. EMA said go for full approval and the reasoning behind this is they liked what they saw nothing less. You don't get picked to play from a bad try out.
I see AH is $8.23. eom
The EMA saw the full data and requested they go for full approval. Sounds in the bag to me.
I'm a bit of an optimist.